MediciNova, Inc. (MNOV)
| Previous Close | 1.4300 |
| Open | 1.4000 |
| Bid | 1.0200 x 200 |
| Ask | 1.8000 x 200 |
| Day's Range | 1.3900 - 1.4500 |
| 52 Week Range | 1.2600 - 2.6600 |
| Volume | |
| Avg. Volume | 38,673 |
| Market Cap | 70.136M |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1700 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.00 |
GlobeNewswireMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of chlorine-induced acute respiratory distress syndrome (ARDS). Once issued, this patent is expec
- GlobeNewswire
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
LA JOLLA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to expire no earlier than September 2040. The allowed claims cov
Simply Wall St.MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years ago
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Imagine if you held MediciNova, Inc...
